Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Response to pharmacologic treatments may identify groups of disorders with a common pathophysiology. The authors applied a treatment-response model, based on four classes of antidepressants (tricyclic types,
monoamine oxidase
inhibitors, serotonin uptake inhibitors, and atypical agents), to the medical literature. The model identified eight disorders that may share a pathophysiologic abnormality: major depression, bulimia, panic disorder, obsessive-compulsive disorder, attention deficit disorder with hyperactivity, cataplexy, migraine, and
irritable bowel syndrome
. Phenomenologic and family studies support this grouping. If the model is validated, this family of disorders, which the authors term "affective spectrum disorder," would represent one of the most prevalent diseases in the population.
...
PMID:Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? 200 8
The activity of
monoamine oxidase
(
MAO
) was studied during functional, inflammatory and tumoral diseases of the large intestine. In the patients with the
irritable colon
syndrome, the enzymatic activity was decreased by 34% at the acute stage of the disease and in those with nonspecific ulcerative colitis it was increased by 44%. Follow-ups of
MAO
activity may serve as an indicator of the adequacy and efficiency of the treatment performed.
...
PMID:[The role of monoamine oxidase in large intestine pathology]. 761 5
I2-binding sites (I2-BS) are attributed to be a regulative site on
monoamine oxidase
(
MAO
). The in vivo and in vitro effects of various imidazoline and guanidine derivatives on
MAO
activity and on mitochondrial respiration were studied. Substances with high affinity for I2-BS (antazoline, idazoxan, and cirazoline: IC50 = 20.3, 33.8, and 43.4 microM) had a stronger inhibitory effect on
MAO
activity than did I1-ligands (efaroxan, rilmenidine, clonidine, and moxonidine: IC50 = 277, 801, 1,224, and > 10,000 microM). Substances with the highest inhibitory effects were BDF8082 (IC50 = 1.7 microM) and 2-(2-benzofuranyl)-2-imidazoline (BFI; IC50 = 4.0 microM). The enzyme is inhibited noncompetitively and is reversible, because its activity is completely or partially restored after dialysis. Agmatine, the putative endogenous ligand for
IBS
, also decreased
MAO
activity (IC50 = 168 microM), whereas its precursor, L-arginine, and its metabolite, putrescine, had no effects. In vitro inhibition of
MAO
and mitochondrial respiration by the
IBS
-ligands tested could not be correlated, suggesting no link between the function of the inner and outer mitochondrial membrane.
MAO
activity in vivo was significantly reduced only by pargyline (-95%), BDF8082 (-68%), BFI (-43%), and 1-(m-chlorophenyl)-biguanide (-28%). Catecholamine content of livers obtained from animals treated with different
IBS
-ligands was consequently increased. In conclusion, the strong inhibitory effects of I2 selective imidazoline ligands confirm the existence of I2-BS as a regulatory site on
MAO
.
...
PMID:Modulation of MAO activity by imidazoline and guanidine derivatives. 1041 32
Artificial neural networks were applied to the alcoholism data to reveal nonlinear relationships between intermediate phenotypes, marker identity-by-descent sharing, and the affection status. A variable number of hidden units were considered to achieve a balance between the minimal mean-squared error and over-fitting of the data. The predictability of the affection status based on intermediate phenotype information (event-related potential 300,
monoamine oxidase
, and gender) was 65% to 75%, and sensitivity/specificity ranged around 50% to 80%. The
IBD
approach succeeded in identifying the same marker as previous studies, but also found additional peaks.
...
PMID:Design of artificial neural network and its applications to the analysis of alcoholism data. 1059 40